Hillhouse Capital Management
Hillhouse leads $160m Series B for China's Genor Biopharma
Genor Biopharma, a Shanghai-based innovative drug developer, has raised $160 million in Series B funding led by Hillhouse Capital.
China digital enterprise services provider raises $50m
Hillhouse Capital has led an extended Series A round of funding worth $50 million for Deepexi, a Chinese start-up that provides a suite of smart data services to enterprise customers.
Korea's Kurly raises $164m Series E
Kurly, operator of Korean grocery delivery platform Market Kurly, has raised KRW200 billion ($164 million) Series E round from a group of domestic and international VCs.
China chip maker ASR hits $1.6b valuation at Series D
ASR Microelectronics, a Shanghai-based manufacturer of chips for use in consumer electronics, has closed an extended Series D round of $119 million. The company is now valued at more than $1.6 billion.
Australia's Airwallex gets $160m Series D
The VC divisions of ANZ Bank and Salesforce have led a $160 million Series D round for Australian financial technology company Airwallex.
Deal focus: Yuanfudao stakes its claim
Eight years old and yet to turn a profit, Chinese K-12 online education platform Yuanfudao is now valued at $7.8 billion. Investors say they are comfortable playing the long game
Hillhouse leads $1b round for China’s Yuanfudao
Chinese online education start-up Yuanfudao has seen its valuation soar to $7.8 billion on closing a $1 billion funding round led by Hillhouse Capital.
Hillhouse leads $60m Series B for China biotech player
Hillhouse Capital has led a $60 million Series B round for China’s Iaso Biotherapeutics via its newly established VC unit GL Ventures.
GLP backs $1.37b take-private of Hong Kong's Li & Fung
The founders of Hong Kong-listed Li & Fung have teamed up with PE-owned warehouse operator GLP on a take-private offer that values their company at HK$10.7 billion ($1.37 billion).
Hillhouse establishes China VC unit
Hillhouse Capital has launched a China venture capital arm under the name GL Ventures. The first fund will reportedly be RMB10 billion ($1.4 billion) in size.
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
China's Transcenta secures $100m funding round
Transcenta Holding, a Chinese biotech company formed last year through the merger of MabSpace Bioscience and Hangzhou Just Biotherapeutics (HJB), has raised $100 million in an extended Series B funding round.
Chinese biopharma player secures $100m Series B
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Chinese industrial internet platform gets $42m Series A
Xreacloud, an industrial internet-of-things (IoT) platform incubated by Chinese state-owned construction machinery manufacturer XCMG, has raised RMB300 million ($43 million) in Series A funding.
Delivery Hero to buy Korea's Woowa Brothers for $4b
Food delivery start-up Delivery Hero has agreed to acquire Korean peer Woowa Brothers in a deal that values the target at $4 billion and will facilitate exits for several private equity investors.
Ping An leads $70m Series D for India's CarDekho
China’s Ping An Insurance has led a $70 million Series D round for Indian online auto marketplace CarDekho. It is Ping An’s first venture investment in the country.
Deal focus: Kujiale embraces SaaS
Having struggled to get traction with consumers, Chinese online interior design player Kujiale turned its attentions to enterprise. International expansion is now on the agenda
Hillhouse, Crystal Stream invest African logistics start-up
Lori Systems, one of Africa’s largest logistics coordination platforms, has raised almost $30 million in a Series A round led by Hillhouse Capital and Crystal Stream Capital.
China's I-Mab Biopharma pursues US IPO
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
Hillhouse wins battle for China electronics player Gree
Hillhouse Capital has secured a 15% interest in Gree Electric Appliances, China's leading manufacturer of air conditioners, beating a consortium led by Hopu Investment.
Huaxing, Hillhouse lead $50m round for China's Hetao 101
Hetao 101, a Chinese online education platform dedicated to computer programming for children, has raised $50 million in Series B funding.
Deal focus: Udaan signals India’s digital progress
B2B marketplace Udaan has achieved unicorn status faster than any of its illustrious Indian forbears. A readymade national broadband infrastructure certainly helped
VC-backed Chinese AI companies hit by US blacklisting
Eight Chinese artificial intelligence (AI) start-ups have been blacklisted by the US government. Several have received PE and VC funding, including SenseTime and Megvii Technology.